Live feed07:00:00·236dPRReleasevia QuantisnowOverall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025ByQuantisnow·Wall Street's wire, on your screen.SMMT· Summit Therapeutics Inc.Health Care